2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 20

High Systemic LDL Cholesterol Levels during Experimental Osteoarthritis Lead to Increased Synovial Activation and Ectopic Bone Formation at End-Stage Osteoarthritis, While Excessive Levels Accelerate Development of Joint Pathology Already at Early-Stage Osteoarthritis
Abstract Number: 2453

High-Density Genotyping of Risk Loci in African Americans with RA
Abstract Number: 171

High-Protein Diet (Atkins Diet) and Uric Acid Response
Abstract Number: 2673

High-Throughput Sequencing of 219 Candidate Genes for Identification of SLE-Associated Risk Variants
Abstract Number: 2027

Higher Educational Level Correlates with Retarded Onset and Less Severe Disease in Rheumatoid Arthritis Patients
Abstract Number: 1220

Higher Inflammatory Response in Elderly Patients during Gout Attack
Abstract Number: 1401

Higher-Order Neuropsychological Deficits Are Frequent and Occur Early in RA and SLE: The Impact of Basic Processing Abilities on Psychological Well-Being
Abstract Number: 1968

Highly activated IL-23/Th17 axis and JAK2/STAT3 signal pathway in PBMC of active AS patients involve in pathogenesis of AS
Abstract Number: 216

Hip Adiposity, Not Local Knee Adiposity, Is Associated with Knee Pain Independent of Radiographic Osteoarthritis Severity
Abstract Number: 1169

Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Abstract Number: 2817

Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Abstract Number: 1005

Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K27
Abstract Number: 134

Histopathological Correlation of Ultrasound-Defined Active Synovitis in Patients with Rheumatoid Arthritis in Clinical Remission. Preliminary Results
Abstract Number: 627

HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease
Abstract Number: 1919

HLA-B27 Expression Shapes the Intestinal Microbiota

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].